Navigation Links
Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
Date:9/13/2010

RESEARCH TRIANGLE PARK, N.C., Sept. 13 /PRNewswire/ -- Max Neeman International, a leading Indian CRO, announces the expansion of therapeutic focused device clinical trial services in India. Max Neeman has formed an experienced and world class team of medical device experts specializing in carrying out cardiac device trials – therapeutic, diagnostic and surgical. Coronary artherectomy, cardiac stents, aneurysm, mitral valve regurgitation and acute coronary syndrome form 90% of the total device trial experience. These are multicentric global trials with patients as high as 300.  Along with prior experience of conducting device trials, the specialized Max Neeman team and services adds an enhanced level of company expertise in conducting simple to complex device studies.  Max Neeman also has medical device operations and regulatory experience in various other device therapeutic areas as well including CNS and Ophthalmology.

India is emerging as a destination of choice for medical device development and conducting device trials as the market for percutaneous coronary interventions has expanded.  India's device market is currently valued at US $1.7 Billion and projected to grow at the rate of 23% annually.  Benefits which have accelerated outsourcing of device trials to India include: shortened product development cycle, faster time to market (by approximately 30% due to faster patient recruitment) and testing resulting in significant cost savings of about 40-50%.  Max Neeman International conducts device studies for small to large device firms across the globe delivering high quality results at a lower cost resulting in high client satisfaction.  

About Max Neeman International
Max Neeman International is one of the leading and largest CROs in India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in over 22 cities with 6 regional offices.  Contact Donald Swankie, Vice President of Business Development via email to donald.swankie@neeman-medical.com or call +1.919.424.3345.  For more information please visit www.neeman-medical.com.


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
2. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
3. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
4. PRA Internationals Drug Safety Experts to Speak at Safety Congress
5. Biosystems International Merges With Microbiochips
6. Medizone International Files For Additional Bio-Terrorism Countermeasures Patent Protection
7. International Isotopes Inc. Announces Completion of a Licensing and Permitting Assistance Agreement with URENCO USA
8. Dyadic International and EnGen Bio to Present at Rodman & Renshaw Annual Global Investment Conference
9. Dyadic International Raises Additional $1 Million to Complete $4 Million Convertible Note Offering
10. /C O R R E C T I O N - Mindray Medical International Limited /
11. Ellman International Announces Executive Team Hire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... Zealand , May 24, 2016 ... informatics solutions for the healthcare sector, has been named the ... Zealand Hi-Tech Awards 2016. Dr Bruce Davey ... acknowledgement for our team.  It,s really good to be recognised ... healthcare internationally. Our products are used in 35 countries around ...
(Date:5/24/2016)... , May 24, 2016 Celsion ... drug development company, today provided an update on ... escalating clinical trial combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  GEN-1 is an IL-12 DNA plasmid ...
(Date:5/24/2016)... 2016 The innovator of ... , s first dual therapy stent, introduces catheters ... OrbusNeich, a global company specializing in the provision ... include products to treat peripheral artery disease. The JADE™ ... devices for lower limb and arteriovenous (AV) fistula intervention. ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... May 25, 2016 , ... The Georgia State University College of Law new ... Urban Design Commission. , The annual award recognizes projects, programs, individuals and organizations that ... preservation of its physical heritage and the balance between the old and the new. ...
(Date:5/25/2016)... ... 2016 , ... A new update to Xsens popular data analysis ... a common Wi-Fi network and a mobile device. When paired with Xsens MVN or ... and use a mobile device to control the recording. , “The update adds ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... One Florida-based ... potential patients, according to an article published May 13th on Vanity Fair. ... comfortable with having snippets of their procedures broadcast to more than 800,000 Snapchat fans. ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Bank of America Charitable Foundation has awarded ... provide veterans a pathway to employment and successful careers in healthcare. On Wednesday, May ... Hallack, President and CEO of Medisend, parent organization and home of the General Myers ...
(Date:5/25/2016)... ... May 25, 2016 , ... New studies ... of injured workers across 15 states. The outcomes examined in these studies include ... medical care, and satisfaction with medical care. , “The goal of the studies ...
Breaking Medicine News(10 mins):